Thomas Smith
Stock Analyst at Leerink Partners
(2.15)
# 2,873
Out of 5,122 analysts
63
Total ratings
33.93%
Success rate
9.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $58 | $57.78 | +0.38% | 4 | Jan 21, 2026 | |
| IVA Inventiva | Initiates: Outperform | $12 | $5.95 | +101.68% | 1 | Jan 12, 2026 | |
| ALMS Alumis | Maintains: Outperform | $20 → $32 | $26.35 | +21.44% | 2 | Jan 7, 2026 | |
| EVMN Evommune | Initiates: Outperform | $42 | $18.94 | +121.75% | 1 | Dec 1, 2025 | |
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $1.51 | -33.77% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $4.02 | +123.88% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $3.54 | +97.74% | 7 | Nov 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $6.84 | +470.18% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $6.08 | +327.63% | 1 | Mar 25, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $113.57 | -82.39% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $430 → $435 | $850.87 | -48.88% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $81.65 | -55.91% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $2.33 | +200.43% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $25.15 | -16.50% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $30.37 | +48.17% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $11.45 | -47.60% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $5.78 | +3.81% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $0.62 | +706.32% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $15.03 | +13.11% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $24.27 | +163.70% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $18.50 | +278.38% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $2.15 | +1,109.30% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $29.56 | -59.40% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $23.78 | +1,582.09% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $18.01 | +344.20% | 2 | Dec 8, 2020 |
RAPT Therapeutics
Jan 21, 2026
Downgrades: Market Perform
Price Target: $58
Current: $57.78
Upside: +0.38%
Inventiva
Jan 12, 2026
Initiates: Outperform
Price Target: $12
Current: $5.95
Upside: +101.68%
Alumis
Jan 7, 2026
Maintains: Outperform
Price Target: $20 → $32
Current: $26.35
Upside: +21.44%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $42
Current: $18.94
Upside: +121.75%
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $1.51
Upside: -33.77%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $4.02
Upside: +123.88%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $3.54
Upside: +97.74%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $6.84
Upside: +470.18%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $6.08
Upside: +327.63%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $113.57
Upside: -82.39%
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $850.87
Upside: -48.88%
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $81.65
Upside: -55.91%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $2.33
Upside: +200.43%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $25.15
Upside: -16.50%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $30.37
Upside: +48.17%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $11.45
Upside: -47.60%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $5.78
Upside: +3.81%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $0.62
Upside: +706.32%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $15.03
Upside: +13.11%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $24.27
Upside: +163.70%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $18.50
Upside: +278.38%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $2.15
Upside: +1,109.30%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $29.56
Upside: -59.40%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $23.78
Upside: +1,582.09%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $18.01
Upside: +344.20%